Teva Pharmaceutical Industries (TEVA) Operating Leases (2018 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Operating Leases for 9 consecutive years, with $282.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 4.73% year-over-year to $282.0 million; the trailing twelve-month figure through Jun 2026 stood at $282.0 million (down 4.73% YoY), and the FY2025 full-year result was $288.0 million, down 24.8% from the prior year.
• Operating Leases grew to $282.0 million in Q2 2026 per TEVA's latest filing, from $280.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $442.0 million in Q4 2022 and bottomed at $280.0 million in Q1 2026.
• Historically, Operating Leases has averaged $330.8 million across 5 years, with a median of $310.0 million in 2023.
• The widest YoY moves for Operating Leases: up 5.34% in 2025, down 24.8% in 2025.
• Over 5 years, Operating Leases stood at $442.0 million in 2022, then retreated by 5.66% to $417.0 million in 2023, then retreated by 8.15% to $383.0 million in 2024, then slipped by 24.8% to $288.0 million in 2025, then declined by 2.08% to $282.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $282.0 million, $280.0 million, and $288.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.